Neurogene (NGNE) Total Current Liabilities (2013 - 2026)

Neurogene (NGNE) has 14 years of Total Current Liabilities data on file, last reported at $18.9 million in Q1 2026.

• Quarterly Total Current Liabilities rose 33.86% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.9 million (up 33.86% YoY) and the FY2025 annual result came in at $16.4 million, up 8.27% from the prior year.
• Total Current Liabilities climbed to $18.9 million in Q1 2026, from $16.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $23.0 million in Q4 2023 to a low of $4.9 million in Q2 2023.
• A 5-year average of $12.3 million and a median of $13.1 million in 2024 frame the typical range for Total Current Liabilities.
• The widest YoY moves for Total Current Liabilities: up 245.41% in 2023, down 49.09% in 2023.
• Tracing NGNE's Total Current Liabilities over 5 years: stood at $6.7 million in 2022, then surged by 245.41% to $23.0 million in 2023, then plunged by 34.02% to $15.2 million in 2024, then advanced by 8.27% to $16.4 million in 2025, then rose by 14.96% to $18.9 million in 2026.
• The last three Total Current Liabilities figures came in at $18.9 million (Q1 2026), $16.4 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.